Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.71 USD

96.71
526,084

-0.09 (-0.09%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $96.71 0.00 (0.00%) 7:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (51 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks News

Amedisys & BrightStar Ink Agreement to Expand Personal Care

Amedisys (AMED) strengthens Personal Care business reach by entering into an agreement with BrightStar.

Amedisys Banks on Coronavirus-Driven Growth Amid Cost Woes

Amedisys (AMED) has been benefiting from the recent acquisitions of hospice care providers.

Amedisys (AMED) Earnings and Revenues Beat Estimates in Q2

Amedisys' (AMED) second-quarter results reflect impressive performance by the Hospice division despite pandemic-led challenges.

Amedisys (AMED) Surpasses Q2 Earnings and Revenue Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 69.62% and 4.30%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Amedisys (AMED)

Amedisys (AMED) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Amedisys (AMED) Expected to Beat Earnings Estimates: Should You Buy?

Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amedisys Rides on Coronavirus-Led Business Amid Cost Woes

Amedisys (AMED) while seeing a drop in MIS visits is experiencing steady recovery in referral volumes.

Why the Earnings Surprise Streak Could Continue for Amedisys (AMED)

Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ADUS vs. AMED: Which Stock Is the Better Value Option?

ADUS vs. AMED: Which Stock Is the Better Value Option?

Healthcare for Silver Years to Aid Encompass Health (EHC)

Encompass Health's (EHC) inpatient rehabilitation and home hospice businesses are poised to grow on the back of aging population.

Amedisys Rides on Hospice Arm Expansion Amid Coronavirus Woes

Amedisys (AMED) benefits from the recent acquisitions of hospice care providers, Asana Hospice, RoseRock Healthcare and Compassionate Care Hospice.

DGX vs. AMED: Which Stock Is the Better Value Option?

DGX vs. AMED: Which Stock Is the Better Value Option?

Here's Why You Should Add Ensign Group to Your Portfolio

Strategic initiatives and a healthy balance sheet make Ensign Group (ENSG) an attractive pick for investors.

Amedisys (AMED) Up 2.5% Since Last Earnings Report: Can It Continue?

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amedisys (AMED) Broadens Hospice Base With AseraCare Buyout

Amedisys (AMED) expects AseraCare business to add greater scale to its existing nationwide network.

Sapna Bagaria headshot

Hospital Industry's Dull Near-Term Outllook Induced by Coronavirus

Revenue loss and cost rise due to coronavirus outbreak put hospital companies in a tight spot.

The Zacks Analyst Blog Highlights: Brookdale Senior Living, The Ensign Group, Amedysis and Chemed

The Zacks Analyst Blog Highlights: Brookdale Senior Living, The Ensign Group, Amedysis and Chemed

Aparajita Dutta headshot

Silver Tsunami to Hit the United States: 4 Stocks in Focus

There are approximately 35 million Americans aged 65 or older currently and this number is expected to double in the next 25 years.

Amedisys (AMED) Q1 Earnings Beat, Operating Margin Falls

Amedisys (AMED) notes that COVID-19 started impacting its volumes and costs beginning the second half of March.

Amedisys (AMED) Beats Q1 Earnings Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 8.25% and -4.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks.com featured highlights include: Vertex Pharmaceuticals, Alibaba, Amedisys and Fabrinet

Zacks.com featured highlights include: Vertex Pharmaceuticals, Alibaba, Amedisys and Fabrinet

Sumit Singh headshot

Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio

Interest Coverage Ratio suggests how many times the interest could be paid from earnings and gauges the margin of safety a firm has for paying interest.

Zacks.com featured highlights include: NEE, FNV, AMED, ATO and COST

Zacks.com featured highlights include: NEE, FNV, AMED, ATO and COST

Bet on These 5 Low Leverage Stocks to Avoid Huge Losses

With the earnings season in full swing, the real challenge for an investor is determining whether an organization's debt level is sustainable.